NCT06832904View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions
HER2-positive Breast CancerNeoadjuvant TherapyPyrotinib
Interventions
DRUG

pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

Receive four neoadjuvant cycles of oral pyrotinib (400 mg) once daily, plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) , nab-paclitaxel (260 mg/m2) and carboplatin（AUC=5）every 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER